180 Life Sciences announces U.S. patent grant for POCD and Canadian Notice of Allowance for Dupuytren's/Frozen Shoulder

FORUM MARKETS Inc

USPTO granted Patent No. 12,325,744 for methods reducing post-operative cognitive decline.
Canadian IPO issued Notice of Allowance for patent covering IL-33 antagonist treatment of localized fibrotic disorders.
U.S. patent is licensed from The Kennedy Trust; Canadian patent is solely owned by 180 Life Sciences.
Company continues strategic discussions for legacy IP but no definitive transaction agreed.
CEO Blair Jordan says patents enhance shareholder value as company pivots to iGaming sector.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.